Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

eryaspase (L-asparaginase encapsulated in red blood cells)

IV infusion 100 U/kg

DRUG

Gemcitabine

IV infusion 1000 mg/m2

DRUG

Carboplatin

IV infusion AUC2

Trial Locations (16)

5000

Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok

6000

Bacs Kiskun Megyei Korhaz, Kecskemét

Unknown

ZNA Middelheim, Antwerp

Institut Jules Bordet, Brussels

UZ Brussel, Brussels

Grand Hôpital de Charleroi asbl, Charleroi

Clinique Sainte-Elisabeth, Namur

Debreceni Egyetem - Klinikai Kozpont - Onkologiai Klinika, Debrecen

Complejo Hospitalario Universitario A Coruña, A Coruña

Hospital Universitario Germans Trias i Pujol, Badalona

Hospital Universitario Arnau Vilanova, Lleida

Fundacion Jimenez Diaz, Madrid

Hospital Clinico San Carlos, Madrid

Hospital Universitario Quirón Madrid, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario Virgen del Rocio, Seville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ERYtech Pharma

INDUSTRY